Inventiva
Market Cap
€415.3m
Last Updated
2020/12/02 19:16 UTC
Data Sources
Company Financials +
Executive Summary
Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 6.9% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet with limited growth.
Share Price & News
How has Inventiva's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IVA is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: IVA's weekly volatility has decreased from 32% to 6% over the past year.
Market Performance
7 Day Return
-5.9%
IVA
6.5%
FR Biotechs
0.5%
FR Market
1 Year Return
219.6%
IVA
34.5%
FR Biotechs
-0.1%
FR Market
Return vs Industry: IVA exceeded the French Biotechs industry which returned 40.9% over the past year.
Return vs Market: IVA exceeded the French Market which returned 1% over the past year.
Shareholder returns
| IVA | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.9% | 6.5% | 0.5% |
| 30 Day | -1.7% | 13.6% | 17.1% |
| 90 Day | 4.8% | 29.8% | 11.8% |
| 1 Year | 219.6%219.6% | 34.5%34.5% | 1.9%-0.1% |
| 3 Year | 80.5%80.5% | -29.5%-29.6% | 17.6%7.9% |
| 5 Year | n/a | -60.3%-60.5% | 52.7%32.0% |
Long-Term Price Volatility Vs. Market
How volatile is Inventiva's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
How Is Inventiva's (EPA:IVA) CEO Compensated?1 month ago | Simply Wall St
Is Inventiva (EPA:IVA) Weighed On By Its Debt Load?2 months ago | Simply Wall St
Inventiva S.A. (EPA:IVA) Analysts Just Trimmed Their Revenue Forecasts By 22%Valuation
Is Inventiva undervalued compared to its fair value and its price relative to the market?
7.82x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IVA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IVA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IVA is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: IVA is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IVA is overvalued based on its PB Ratio (7.8x) compared to the FR Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Inventiva forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
-6.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IVA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IVA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IVA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IVA's revenue (51.5% per year) is forecast to grow faster than the French market (7.3% per year).
High Growth Revenue: IVA's revenue (51.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IVA is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Inventiva performed over the past 5 years?
-32.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IVA is currently unprofitable.
Growing Profit Margin: IVA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IVA is unprofitable, and losses have increased over the past 5 years at a rate of 32% per year.
Accelerating Growth: Unable to compare IVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).
Return on Equity
High ROE: IVA has a negative Return on Equity (-60.7%), as it is currently unprofitable.
Next Steps
Financial Health
How is Inventiva's financial position?
Financial Position Analysis
Short Term Liabilities: IVA's short term assets (€60.2M) exceed its short term liabilities (€25.2M).
Long Term Liabilities: IVA's short term assets (€60.2M) exceed its long term liabilities (€1.8M).
Debt to Equity History and Analysis
Debt Level: IVA's debt to equity ratio (24%) is considered satisfactory.
Reducing Debt: IVA's debt to equity ratio has increased from 0.9% to 24% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IVA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IVA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16% each year
Next Steps
Dividend
What is Inventiva current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IVA's dividend in 3 years as they are not forecast to pay a notable one for the French market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
9.1yrs
Average management tenure
CEO
Frédéric Cren (54 yo)
9.92yrs
Tenure
€373,583
Compensation
Mr. Frédéric Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...
CEO Compensation Analysis
Compensation vs Market: Frédéric's total compensation ($USD451.35K) is about average for companies of similar size in the French market ($USD556.39K).
Compensation vs Earnings: Frédéric's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.92yrs | €373.58k | 14.86% € 61.7m | |
| Co-Founder | 9.92yrs | €262.41k | 10.12% € 42.0m | |
| Chief Financial Officer | 8.33yrs | no data | no data | |
| Legal Director | no data | no data | no data | |
| Head of Human Resources | no data | no data | no data | |
| Head of Pharmacokinetics | no data | no data | no data | |
| Head of Chemistry | no data | no data | no data | |
| Head of Biology & Pharmacology | no data | no data | no data | |
| Head of Business Development | no data | no data | no data | |
| Chief Medical Officer | 0.92yr | no data | no data |
9.1yrs
Average Tenure
56yo
Average Age
Experienced Management: IVA's management team is seasoned and experienced (9.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.92yrs | €373.58k | 14.86% € 61.7m | |
| Independent Director | 3.83yrs | €54.00k | 0% € 0 | |
| Independent Director | 3.83yrs | €43.00k | 0% € 0 | |
| Chairman of Scientific Advisory Board | no data | €16.00k | no data | |
| Independent Director | 2.58yrs | €31.00k | no data | |
| Independent Director | 1.58yrs | €20.00k | no data | |
| Independent Director | 1.58yrs | €23.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data |
3.2yrs
Average Tenure
56yo
Average Age
Experienced Board: IVA's board of directors are considered experienced (3.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.6%.
Top Shareholders
Company Information
Inventiva S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Inventiva S.A.
- Ticker: IVA
- Exchange: ENXTPA
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €415.257m
- Shares outstanding: 38.38m
- Website: https://www.inventivapharma.com
Number of Employees
Location
- Inventiva S.A.
- 50 rue de Dijon
- Daix
- Burgundy
- 21121
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IVA | ENXTPA (Euronext Paris) | Yes | Ordinary Shares | FR | EUR | Feb 2017 |
| 0RNK | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Feb 2017 |
| IVEV.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Feb 2017 |
| 6IV | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Feb 2017 |
| IVAP | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Feb 2017 |
| 6IVA | DB (Deutsche Boerse AG) | ADS | DE | EUR | Jul 2020 | |
| IVA | NasdaqGM (Nasdaq Global Market) | ADS | US | USD | Jul 2020 |
Biography
Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to tre...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/12/02 19:16 |
| End of Day Share Price | 2020/12/02 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.